BevicortTM
Formoterol Fumarate + Glycopyrronium Bromide + Budesonide
Beta-2 Agonist + Anticholinergic + Corticosteroid (Antiasthma)
Indication:
For the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and/or emphysema.
Dosage & Administration:
Adults: Should be administered 2 puffs twice daily, in the morning and in the evening.
Preparation:
BevicortTM HFA Inhaler: Each puff delivers Formoterol Fumarate 5.5 mcg, Glycopyrronium Bromide 10.4 mcg and Budesonide 182 mcg. Each Inhaler delivers 120 puffs.